• This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Sun - Fri 8:00 - 20:30
coflex
Pin It

Paradigm Spine, LLC, a leader in providing solutions for the treatment of lumbar spinal stenosis, today announced the issuance of an AmeriHealth Caritas Clinical Policy, dated September 1, 2018, for the exclusive coverage of the coflex® interlaminar stabilization device for the treatment of lumbar spinal stenosis.

Lumbar spinal stenosis ("LSS"), affecting 1.6 million patients annually, is a debilitating and degenerative disease in older patients (>50 years) often associated with significant leg and back pain, leg numbness and weakness, causing a significant reduction in an active lifestyle. Traditional surgical treatment options for LSS include a decompression that removes bone and soft tissue and may also require a fusion to stabilize the spine. The coflex® device is a non-fusion, motion-preserving stabilization implant that is FDA PMA approved for the treatment of lumbar spinal stenosis and is used in conjunction with a decompression, or used in lieu of a spinal fusion.

Marc Viscogliosi, Paradigm Spine Chairman & CEO, commented, "With this continued payor coverage momentum, we look forward to further expanding access to our coflex® solution, which is backed by more than 90 peer-reviewed published articles, including landmark long-term follow-up clinical studies, and spine medical society guidelines."

For additional information visit www.paradigmspine.com or www.coflexsolution.com.

Pin It
Company Name: Paradigm Spine, LLC
About Company: Paradigm Spine, LLC, founded in 2004, is a privately held company and remains focused on the design and development of solutions for the disease management of spinal stenosis. The Company's signature product is the coflex® Interlaminar Stabilization® device, which is currently used in over 60 countries worldwide. coflex® is the only lumbar spinal device that has produced Level I evidence in two separate prospective, randomized, controlled studies against two different control groups, changing the standard of care for lumbar spinal stenosis treatment.

We use cookies to ensure you get the best experience on this website Privacy Policy